Table 4.
Studies Including Patients with Limited-Stage Small-Cell Lung Cancer Treated with Hypofractionated Radiotherapy.
| Author | Year | HFRT Schedule (Gy/fx) | n | Overall Survival (%) | ≥Grade 3 Esophageal Toxicity (%) | ≥Grade 3 Lung Toxicity (%) | |
|---|---|---|---|---|---|---|---|
| 2-Year | 5-Year | ||||||
| Murray et al. [10] * | 1993 | 40/15 | 155 # | 40 | 20 | 43.6 | 3.2 |
| Videtic et al. [32] | 2003 | 40/15 | 122 | 27 | 9 | - | - |
| Bettington et al. [8] | 2013 | 40/15 | 38 | - | 20 | - | - |
| Socha et al. [33] | 2015 | 42/15 | 100 | 52 | 31 | 0 | 0 |
| Grønberg et al. [7] | 2016 | 45/15 | 84 | 42 | - | 31 | 6 |
| Turgeon et al. [31] * | 2017 | 40/15 | 68 | 53 | 35 | 9 | 1 |
| Zhang et al. [34] | 2017 | 55/20 | 69 | 62 | - | 12 | 10 |
| Zayed et al. [9] | 2020 | 40–45/15–20 | 56 | - | 26 | 6+ | 3+ |
| Present study | 2020 | 40/15 | 63 | 47 | 24 | 14 | 8 |
Abbreviations: HFRT—hypofractionated, Gy—gray, fx—fractions, OS—overall survival, LRR—locoregional recurrence, GI—gastrointestinal; * Randomized trials; # Only the early concurrent therapy arm is included.